Off-Label Use of Liraglutide in the Management of a Pediatric Patient with Type 2 Diabetes Mellitus

Micale, Sara J.; Kane, Michael P.; Hogan, Eileen
January 2013
Case Reports in Pediatrics;2013, p1
Academic Journal
Liraglutide is a glucagon-like peptide 1 (GLP-1) analog indicated for the treatment of type 2 diabetes mellitus as an adjunct to diet and exercise in adults. Liraglutide lowers blood glucose levels by stimulating insulin secretion and decreasing glucagon release in glucose-dependent manners, increases satiety, and delays gastric emptying. Liraglutide, unlike metformin and insulin, is not approved for use in the pediatric population. We report the successful off-label use of liraglutide in an obese, 16 year old Caucasian female with type 2 diabetes mellitus.


Related Articles

  • Practical applications of therapy with a glucagon-like peptide- 1 receptor agonist. Shomali, Mansur E. // Journal of Family Practice;Sep2009 Treating Patients, Vol. 58, pS35 

    The article discusses various studies which showed medical applications of glucagon-like peptide-1 (GLP-1) receptor agonist to treat patients with type 2 diabetes mellitus (T2DM) in the U.S. It found that the treatment regimen is effective after the initiation of lifestyle management and...

  • Selecting among ADA/EASD tier 1 and tier 2 treatment options. McGill, Janet B. // Journal of Family Practice;Sep2009 Treating Patients, Vol. 58, pS26 

    The article focuses on the study conducted by the American Diabetes Association/European Association for the Study of Diabetes (ADA/EASD) on the effectiveness of metformin therapy and lifestyle management to patients with type 2 diabetes mellitus (T2DM) in the U.S. Insulin and sulfonylureas...

  • In metformin-treated type 2 diabetes, weekly dulaglutide was noninferior to daily liraglutide for HbA1c levels. Morey-Vargas, Oscar L.; Shah, Pankaj // Annals of Internal Medicine;11/18/2014, Vol. 161 Issue 10, pJC9 

    The article offers information on a study based on effectiveness of dulaglutide noninferior to daily liraglutide for reducing hemoglobin (Hb) A1c levels in patients with uncontrolled type 2 diabetes who are receiving metformin therapy. It mentions that Glucagon-like peptide-1 (GLP-1) analogues...

  • Liraglutide: Promise of the Incretin Class. Kuritzky, Louis // Clinical Oncology Alert;Mar2009 Clinical Briefs, p5 

    The article discusses research being done on liraglutide, a synthetic glucagon-like peptide-1. It references a study conducted by M. Nauck et al published in a 2009 issue of "Diabetes Care." Researchers performed a double-blind, controlled trial of liraglutide (LIR) versus glimepiride or placebo...

  • Dipeptidyl Peptidase-4 Inhibitors Administered in Combination With Metformin Result in an Additive Increase in the Plasma Concentration of Active GLP-1. Migoya, E. M.; Bergeron, R.; Miller, J. L.; Snyder, R. N. K.; Tanen, M.; Hilliard, D.; Weiss, B.; Larson, P.; Gutierrez, M.; Jiang, G.; Liu, F.; Pryor, K. A.; Yao, J.; Zhu, L.; Holst, J. J.; Deacon, C.; Herman, G.; Thornberry, N.; Amatruda, J.; Williams-Herman, D. // Clinical Pharmacology & Therapeutics;Dec2010, Vol. 88 Issue 6, p801 

    The aim of the study was to investigate the effects of a dipeptidyl peptidase-4 (DPP-4) inhibitor, of metformin, and of the combination of the two agents, on incretin hormone concentrations. Active and inactive (or total) incretin plasma concentrations, plasma DPP-4 activity, and preproglucagon...

  • Pharmacologic Treatment Strategies in Children with Type 2 Diabetes Mellitus. Urakami, Tatsuhiko; Kuwabara, Remi; Habu, Masako; Yoshida, Ayako; Okuno, Misako; Suzuki, Junichi; Takahashi, Shori; Mugishima, Hideo // Clinical Pediatric Endocrinology;Jan2013, Vol. 22 Issue 1, p1 

    We treated 80 obese and 28 nonobese children diagnosed as having type 2 diabetes mellitus (T2DM). Among these patients, 26 obese and 23 nonobese children were assigned to pharmacologic therapies during the course of diabetes. Pharmacologic therapies were started if the HbAlc (NGSP) value...

  • GLP-1 receptor agonist-induced polyarthritis: a case report. Ambrosio, Maria; Monami, Matteo; Sati, Lavinia; Marchionni, Niccolò; Bari, Mauro; Mannucci, Edoardo // Acta Diabetologica;Aug2014, Vol. 51 Issue 4, p673 

    Occasional cases of bilateral, symmetrical, seronegative polyarthritis have been reported in patients treated with dipeptidyl peptidase-4 inhibitors (Crickx et al. in Rheumatol Int, ). We report here a similar case observed during treatment with a GLP-1 receptor agonist. A 42-year-old man with...

  • Glucagon-like peptide-1 receptor agonists for intensifying diabetes treatment. Bush, Michael A. // Journal of Family Practice;Sep2011 Supplement 1, Vol. 60, pS11 

    The article focuses on the efficacy of glucagon-like peptide-1 receptor (GLP-1R) agonists in diabetic treatment. It mentions that GLP-1R agonist with the combination of lifestyle management can reduce the glycated hemoglobin (A1C) level by 0.5% to 1.5%. It states the effectiveness of GLP-1R...

  • The Shot Clock. Berg, Erika Gebei // Diabetes Forecast;Aug2014, Vol. 67 Issue 8, p28 

    The article focuses on the use of metformin in treating type 2 diabetes. It mentions that diabetes medication need daily doses. It offers information on glucagon-like peptide 1 (GLP-1) which is released by the small intestine after eating and traveling. It mentions that GLP-1 receptors are found...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics